Scientific publications

Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis

May 15, 2019 | Magazine: Future Oncology

Zhou Q (1), Wu YL (1), Corral J (2), Nakagawa K (3), Garon EB (4), Sbar EI (5), Wang T (6), Sandin R (7), Noonan K (6), Gernhardt D (6), Mok TS (8).

(1) Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.
(2) Clínica Universidad de Navarra, Madrid, 28027, Spain.
(3) Kindai University Hospital, Osaka, 589-8511, Japan.
(4) David Geffen School of Medicine, University of California at Los Angeles, Santa Monica, CA 90404, USA.
(5) Pfizer Inc., Collegeville, PA 19426, USA.
(6) Pfizer Inc., Groton, CT 06340, USA.
(7) Pfizer Inc., Sollentuna, 191 38, Sweden.
(8) State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.


Aim: This pooled safety analysis was conducted to analyze incidence and management of key dacomitinib-associated adverse drug reactions (ADRs).

Patients & methods: Patients with EGFR mutation-positive advanced non-small-cell lung cancer who received first-line dacomitinib at the 45 mg/day recommended starting dose were included. ADRs were identified based on reasonable association with EGFR tyrosine kinase inhibitors.

Results: Overall, 251/255 patients (98%) experienced ADRs. The most common were diarrhea, rash, stomatitis, nail disorder and dry skin. Dose interruptions and dose reductions were reported in 47 and 52% of patients, respectively. Fewer grade 3 key ADRs were observed following dose reductions.

Conclusion: Dacomitinib was generally tolerable. Most reported ADRs were known to be associated with EGFR tyrosine kinase inhibitors and were managed with standard medical management and dose modifications.

CITATION  Future Oncol. 2019 May;15(13):1481-1491. doi: 10.2217/fon-2018-0944. Epub 2019 Mar 6.

Our authors